



CIN : L99999MH1951PLC008485

Regd. Office : A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India

Tel : +91-22-67980888 , ● Fax : +91-22-67980899 , ● Email : [contact@dil.net](mailto:contact@dil.net) , ● Website: [www.dil.net](http://www.dil.net)

Ref: DIL/BSE/2019-20/F.No.:49

May 30, 2019

**Corporate Relations**  
**BSE Limited,**  
**Phiroze Jeejeebhoy Towers,**  
**Dalal Street, Fort,**  
**Mumbai – 400 001**

Dear Sir,

**Sub.: Intimation of Investor Presentation for May 2019**

**Ref: Scrip Code: 506414**

Further to our intimation dated May 24, 2019 regarding approval of Audited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter and financial year ended March 31, 2019, we hereby enclose a copy of Investor Presentation for May 2019.

The said Investor Presentation is also available on Company's website [www.dil.net](http://www.dil.net)



Kindly take the same on records.

Thanking you,

Yours faithfully,  
for **DIL LIMITED**

**Srikant N Sharma**  
**Company Secretary**  
CS Membership No: F3617  
*A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610*

Encl: As above



This presentation and the accompanying slides (the “Presentation”), which have been prepared by **DIL Limited**. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.


# Another Year of Strong Performance

Revenue\* (Rs. Crs)

EBITDA\* (Rs. Crs)

PAT^ (Rs. Crs)


**FY19 Revenues and Profitability have surpassed FY18**




**We are confident of achieving CAGR of ~15% to 20% growth over next 5 years**

# Fermenta Biotech: Financial Highlights


## Revenue\* (Rs. Crs)



## EBITDA\* (Rs. Crs)



## PAT^ (Rs. Crs)



# Fermenta Biotech: Profit and Loss



Fermenta Biotech Limited

Particulars (Rs. Crs)	FY19	FY18	Y-o-Y
<b>Revenue</b>	389.3	292.0	33.3%
Other Income	12.1	8.5	
<b>Total Revenue</b>	401.3	300.5	33.6%
Raw Material	92.3	79.8	
Employee Expenses	47.5	34.1	
Other Expenses	102.0	83.1	
<b>EBITDA</b>	159.5	103.5	54.2%
<b>EBITDA Margin %</b>	39.8%	34.4%	
Depreciation	8.1	7.7	
<b>EBIT</b>	151.4	95.8	58.1%
<b>EBIT Margin %</b>	37.7%	31.9%	
Finance Cost	4.7	3.0	
<b>PBT</b>	146.7	92.8	58.1%
Tax	33.7	20.4	
<b>PAT</b>	112.96	72.3512	56.1%
<b>PAT Margin %</b>	28.15%	24.08%	
EPS	63.8	40.7	

- Vitamin D3 for Human use which is 33.6% of overall revenues has witnessed a growth of 54.3% in FY19 on a YoY basis
- Vitamin D3 for Animal Feed use which is 49.8% of overall revenues has witnessed a growth of 30.2% in FY19 on a YoY basis
- Enzymes manufacturing business revenue growth at 140.6% from Rs.5.7 Crores in FY18 to Rs.13.8 Crores in FY19 which is a very highly scalable business once it achieves an optimum scale/size

# Fermenta Biotech - Balance Sheet



Fermenta Biotech Limited

<b>EQUITY AND LIABILITIES</b>	<b>Mar-19</b>	<b>Mar-18</b>	<b>ASSETS</b>	<b>Mar-19</b>	<b>Mar-18</b>
<b>Equity</b>			<b>Non-current assets</b>		
Equity Share capital	17.7	17.7	Property, plant and equipment	78.0	74.6
Non Controlling Interest			Capital work-in-progress	20.7	2.5
Other equity	267.8	155.0	Intangible assets	2.3	2.1
<b>Sub-total - Shareholders' funds</b>	<b>285.6</b>	<b>172.7</b>	Intangible Assets Under Development	0.9	1.0
			Investment in Subsidiaries & associates	0.4	0.4
<b>LIABILITIES</b>			<b>Financial assets</b>		
<b>Non-current liabilities</b>			Investments	0.0	0.0
<b>Financial liabilities</b>			Loans	0.3	0.1
Borrowings	8.1	3.4	Other financial assets	4.6	4.3
Provisions	4.4	2.0	Other non-current assets	28.1	4.5
Deferred tax liabilities (net)	3.7	2.2	Non-Current Tax Assets	0.0	0.1
<b>Sub-total - Non-current liabilities</b>	<b>16.2</b>	<b>7.6</b>	<b>Sub-total - Non-Current Assets</b>	<b>135.2</b>	<b>89.5</b>
<b>Current liabilities</b>			<b>Current assets</b>		
<b>Financial liabilities</b>			Inventories	87.7	51.2
Borrowings	53.7	24.1	<b>Financial assets</b>		
Trade payables	41.2	38.9	Trade receivables	65.7	68.6
Other financial liabilities	25.7	14.4	Cash and cash equivalents	39.2	21.2
Other current liabilities	2.5	4.6	Bank balances other than Cash and Cash equivalents	50.2	9.3
Provisions	0.4	0.3	Loans	11.5	0.0
Current tax liabilities (net)	5.1	3.8	Other financial assets	2.3	0.2
<b>Sub-total - Current liabilities</b>	<b>128.6</b>	<b>86.1</b>	Other current assets	38.6	26.2
			<b>Sub-total - Current Assets</b>	<b>295.2</b>	<b>176.8</b>
			Assets Classified as held for Sale		
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>430.4</b>	<b>266.3</b>	<b>TOTAL - ASSETS</b>	<b>430.4</b>	<b>266.3</b>

**Strong Credit Rating of CARE A- for Long Term and CARE A2 for Short Term Loans with "Stable" Outlook**

# Consolidated Profit and Loss



Fermenta Biotech Limited

Particulars (Rs. Crs)	FY19	FY18	YoY
<b>Revenue</b>	<b>404.7</b>	<b>302.7</b>	<b>33.7%</b>
Other Income	12.4	8.9	
<b>Total Revenue</b>	<b>417.0</b>	<b>311.6</b>	<b>33.8%</b>
Raw Material	92.3	79.8	
Employee Expenses	53.2	39.8	
Other Expenses	110.4	90.0	
<b>EBITDA</b>	<b>161.2</b>	<b>102.0</b>	<b>58.1%</b>
<b>EBITDA Margin %</b>	<b>38.7%</b>	<b>32.7%</b>	
Depreciation	11.9	12.4	
<b>EBIT</b>	<b>149.4</b>	<b>89.6</b>	<b>66.7%</b>
<b>EBIT Margin %</b>	<b>35.8%</b>	<b>28.8%</b>	
Finance Cost	20.7	13.6	
<b>PBT</b>	<b>128.7</b>	<b>76.0</b>	<b>69.4%</b>
Tax	10.8	21.1	
<b>PAT</b>	<b>117.9</b>	<b>54.8</b>	<b>115.0%</b>
<b>PAT Margin %</b>	<b>28.3%</b>	<b>17.6%</b>	
Share of profit /(loss) of JV's and Associates	-0.4	-8.5	
<b>PAT after share of profit / (loss) of JV's and Associates</b>	<b>117.47</b>	<b>46.34</b>	<b>153.5%</b>
Minority Interest	-7.1	-12.6	
<b>PAT after MI</b>	<b>110.36</b>	<b>33.71</b>	<b>227.3%</b>
EPS (in Rs.)	120.31	36.75	


# Consolidated Balance Sheet

<b>EQUITY AND LIABILITIES</b>	<b>Mar-19</b>	<b>Mar-18</b>
<b>Equity</b>		
Equity Share capital	4.6	2.3
Non Controlling Interest	18.1	11.0
Other equity	227.9	122.2
<b>Sub-total - Shareholders' funds</b>	<b>250.6</b>	<b>135.4</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
Borrowings	135.2	135.4
Other financial liabilities	1.9	3.7
Provisions	6.3	2.7
Deferred tax liabilities (net)	3.7	2.2
Other non-current liabilities	1.3	1.7
<b>Sub-total - Non-current liabilities</b>	<b>148.4</b>	<b>145.7</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
Borrowings	60.2	29.9
Trade payables	42.7	40.1
Other financial liabilities	42.5	23.3
Other current liabilities	4.9	6.1
Provisions	0.5	0.5
Current tax liabilities (net)	5.1	3.8
<b>Sub-total - Current liabilities</b>	<b>156.0</b>	<b>103.6</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>554.9</b>	<b>384.6</b>

<b>ASSETS</b>	<b>Mar-19</b>	<b>Mar-18</b>
<b>Non-current assets</b>		
Property, plant and equipment	97.3	90.6
Capital work-in-progress	20.7	2.5
Other intangible assets	2.3	2.1
Intangible Assets Under Development	0.9	1.0
Investment in Subsidiaries & associates		1.2
Goodwill	4.1	4.1
Investment Property	73.8	80.5
<b>Financial assets</b>		
Investments	0.6	0.1
Loans	0.3	0.4
Share Application Money	6.0	7.9
Other financial assets	4.6	4.8
Other non-current assets	22.4	6.0
Deferred Tax Assets	23.0	
Non Current tax assets (net)	3.3	1.1
<b>Sub-total - Non-Current Assets</b>	<b>259.3</b>	<b>201.2</b>
<b>Current assets</b>		
Inventories	87.7	51.2
<b>Financial assets</b>		
Investments	1.1	1.1
Trade receivables	65.5	68.7
Cash and cash equivalents	40.8	32.4
Bank balances other than Cash and Cash equivalents	50.4	0.2
Loans	11.8	0.1
Other financial assets	2.6	0.9
Other current assets	35.7	27.7
<b>Sub-total - Current Assets</b>	<b>295.6</b>	<b>182.3</b>
Assets Classified as held for Sale		
<b>TOTAL - ASSETS</b>	<b>554.9</b>	<b>384.6</b>

# Debt Break-up


Rs. Crores



# Status of Non-core Investments

Associates / Joint Venture	Status
Agastya Films LLP (Joint Venture)	Exited the Joint Venture as on 1 <sup>st</sup> January 2019
Zela Wellness Pvt Ltd (Associate)	No more an associate company post reduction of stake from 1 <sup>st</sup> January 2019
Health & Wellness Pvt Ltd (Associate)	All investments provided for as on 31 <sup>st</sup> March 2019 financials

# Six Decades of History





**DIL Ltd. through its subsidiary is primarily engaged in the business of Pharmaceuticals and Integrated Biotechnology**

## 1 Fermenta Biotech (91.2% Subsidiary)



- A company focused on research, development and product delivery in pharmaceutical and integrated biotechnology
- Only manufacturer of Vitamin D3 in India; amongst few leading producers in the world

## 2 Assets


- **Thane One** – ~200,000 sq ft. leasable area, which is currently 100% occupied + has an additional **freehold land** of ~5.5 acres in Thane
- **Ceejay House** – ~10,000 sq ft. area leased
- ~45 acres of **Freehold Land** in Takawe, Pune



API




Integrated Biotechnology



Vitamin D3

# Through Merger of FBL with DIL



# Contours of the Merger

## Merger Consideration

- There is no cash consideration
- 100 Equity shares of DIL of Rs. 10 each fully paid up for every 1,006 equity shares of FBL of Rs. 10 each fully paid up
- Subject to members approval, the Board of Directors of DIL Ltd at its meeting held on June 18, 2018 approved:
  - Split / sub-division of equity shares from face value of Rs. 10 each to face value of Rs. 5 each
  - Issue of Bonus equity shares in proportion of 1:1, having face value of Rs. 5 each
  - Accordingly, the number of shares to be issued to the FBL shareholders will undergo change i.e. 100 equity shares of DIL of Rs. 5 each fully paid up for every 251 equity shares of FBL of Rs. 10 each fully paid up

Category	Existing Shareholding	Post Merger Shareholding
Promoters	62.59%	58.93%
Public	37.41%	41.07%
<b>Total</b>	<b>100.00%</b>	<b>100.00%</b>

## Current Status:

Applied to NCLT, Mumbai for scheme approval

## **Fermenta Biotech (91.2 % Subsidiary)**

- A company focused on research, development and product delivery in biotechnology as well as pharmaceutical and environmental solutions
- Only manufacturer of Vitamin D3 in India; amongst few leading producers in the world

## **Assets**

- Thane One
- Ceejay House
- Land in Takawe, Pune

Going Forward


## **Focus on Fermenta**

- Focused towards expanding the product portfolio of Fermenta Biotech
- Positioning ourselves as Nutrition Supplement Business


## **Assets**

- Leverage on available real estate assets for the use of expansion and growth within Fermenta Biotech

# Fermenta's Portfolio Outlook




## Excellence in Operations




# The Emerging Nutraceuticals Market



**Global (USD Billion)**



**Domestic (USD Billion)**



**Nutraceutical Market Size**

**Key Drivers**

Well developed/  
Matured market

Well defined value  
chain


Retail/Consumer  
driven approach

Ascertained  
awareness

Large population with increasing disposable  
income, emerging market

Favourable government policies for food  
fortification


# Consistent Dividend Paying




*About Fermenta  
Biotech Limited*



# Three Decades of Fermenta...



# ..progress over the Last Decade



# Experienced Board of Directors



Fermenta Biotech Limited

**Mr. Sanjay Buch**

Chairman

**Mr. Satish  
Varma**

Managing Director

**Ms. Anupama  
Datla Desai**


Executive Director

**Mr. Krishna Datla**

Non- Executive Director

**Dr. Gopakumar  
Nair**

Independent Director



## Applications

### Human Health



Pharmaceuticals



Dietary Supplements



Food

### Animal Health




Veterinary



Feed

# Vitamin D – Important Facts to Know



# Vitamin D3 – Our Proprietary Technology



Fermenta Biotech Limited


## Pioneering

Use of proprietary technology to manufacture Vitamin D3 API in India




## Scale

It is among the top three producers of Vitamin D3 API in the world




## Integrated

Fully integrated Vitamin D3 API manufacturer benefiting from superior quality and cost effectiveness



## Natural

The cholesterol used, is obtained from sheep wool from TSE/BSE risk free countries



## Unique

One of three CEP-certified companies worldwide; its products and manufacturing facilities have been certified by various international regulatory bodies



## Knowledge Capital

It has been manufacturing Vitamin D3 for over 50 years with a base of over 300+ customers



## One Stop Shop

It manufactures Vitamin D3 for various applications (human and veterinary healthcare, Animal Feed)



## Standardized

Manufacturing facilities are benchmarked with the best global standards, backed by dedicated professionals and accreditations from a large number of global regulatory agencies



## Global Presence

- Nascent and Mature business mix
- **Globally Recognized Plants** for key products
- Proprietary IPR-driven research
- Multi-decadal **Experience**
- Competent and experienced **Human Capital**
- Governance focus
- Global quality **Certifications**
- **50 countries** across the world



## Niche Presence

- Growing number of Multi-year accounts
- Among the **Worlds Largest D3 Makers** and **Leading Phenyramidol Manufacturer**
- Among top pioneering companies to **introduce enzymatic antibiotics manufacturing technology**
- Among few non-European companies with a **CEP accreditation** by EQDM for Vitamin D3



## Financial Strength

- **Healthy Balance Sheet**
- Profitable **Growth**
- **Low cost borrowings** due to significant exports



- For over 25 years, Fermenta Biotech Ltd. (FBL) has been dedicated towards manufacturing specialty APIs and Bio-Catalysts.
- The Company is a trusted and reliable source of specialty pharmaceutical products worldwide

## Phenyramidol HCl

Phenyramidol Hydrochloride is a unique API. A potent muscle relaxant with concomitant analgesic effect

FBL has been a pioneer in reviving Phenyramidol HCl as an API and has successfully marketed the product in Turkey and India. The formulation of Phenyramidol grew exponentially in Turkey

## Silicon Powder (Activated Dimethicone Powder)

Manufacturing of Silicon Powder (Activated Dimethicone Powder) was a conscious effort by FBL to offer a product that could replace simethicone oil in anti-flatulent oral formulations.

Replacement by silicon powder has helped enhance properties of powdered anti-flatulent oral formulations. Endorsed by one of the most popular pharma brands in Turkey, the product is presently being used in their anti-flatulent and digestive enzyme formulations.



- FBL is a leader in providing immobilized enzymes and enzyme technologies, and proprietary immobilization platforms
- Products are supplied to Sectors like Pharmaceutical, Fine Chemicals to Bioplastics, Cosmetics etc
- Our enzyme technologies for the synthesis of beta lactams and cephalosporin antibiotics offer unique advantages, which are not only scalable but also enable competitive transformation
- Some of the flagship enzyme products range from the classical "white enzyme", Penicillin G amidase-(PA 850) to the more advanced enzyme variants like Novel Penicillin G Amidase and CALB Lipase (CALB10000)
- We also offer enzyme immobilization optimization and supply services of various scale upto multi-ton commercial quantities
- Our special microorganisms, enzymes and platform technologies provide unique advantages in waste water treatment and management

“  
Driven by the  
Discover,  
Develop &  
Deliver  
philosophy  
”



Modern, fully equipped, DSIR approved Research & Development facility complimented by highly skilled and committed scientists.



Providing **Integrated Solutions**, processes and products for Biotech and Active Pharmaceutical Ingredients (API)



**API R&D**, combined with expertise on photochemistry, chromatography and multi-step process development skills



**Biotech R&D** has got wide experience in the areas of bacterial fermentation, enzyme expression, immobilization platforms and process development in various enzymatic applications



**Enzyme technology platform** is aimed at helping companies become environmentally responsible and sustainable (Green Chemistry)



## Quality Assurance

Responsible for

- Implementation of quality systems and release of all manufactured products
- Audits including regulatory (national and international), customer and GMP



## Regulatory Affairs

Ensures compliance with national and international regulatory requirements



## Quality Control



Responsible for all analyses, from analytical support to validations



Shifted to New R&D Centre of 15,000 sq. ft


# Geographical Presence – Manufacturing & Clientele

## Manufacturing & Operating Locations




Supplying More than **300 Customers** both Domestic & International

## Revenue – Breakup – FY19



\*Acquired Land at Sayakha for future expansion of 40,000 Sq.Mt.

# Manufacturing Units – Kullu, Himachal Pradesh



- ✓ Set up the Biotech plant in 1987 to manufacture Penicillin G Amidase and Penicillin G Acylase enzyme and emerged as the leader in enzyme technologies for beta lactam in India
- ✓ Set up Bulk Drug division in 2004 to manufacture various APIs like Vitamin D3, Phenyramidol HCl (Fenyramidol) and Silicon Powder (Activated Dimethicone Powder)
- ✓ Facility is cGMP compliant, supplies its products across the globe

# Manufacturing Units – Dahej Gujarat



✓ Established a green field manufacturing facility at Dahej SEZ Ltd. in 2011 to cater to the growing international market

✓ Site has dedicated manufacturing blocks for API's/Intermediates

✓ Strict adherence to Safety, Health & Environment (SHE) policy

**Both the manufacturing units are registered with US FDA "Food Facility Registration Module (FFRM)"**

# Our Accreditations



US FDA

WHO-GMP



HACCP

OHSAS  
18001:2007




ISO 14001:2015

ISO 14001:2015



Product specific and Site specific




We have been **Investing in Technology** for optimizing process parameters, moderating costs and increasing efficiency

# Fermenta – Historical Performance




Fermenta Biotech Limited


Revenue^ (Rs. Crs)




EBITDA^ (Rs. Crs)




PAT (Rs. Crs)




Cash PAT (Rs. Crs)



EBITDA (%)



PAT (%)



\*As per IND-AS

^Includes Other Income

A modern office lobby with a grey and white tiled wall. The wall features a logo with a stylized '1' and the text 'Thane one'. The lobby is furnished with black leather sofas and a glass coffee table. Large windows and glass partitions are visible in the background.

*About DIL  
Limited*

# Experienced Board of Directors

**Mr. Sanjay Buch**

Chairman (Non - Executive  
and Independent)

**Mr. Krishna Datla**

Managing Director

**Mr. Gopakumar  
Nair**

Additional  
(independent) Director

**Ms. Rajeshwari  
Datla**

Non - Executive Director


**Mr. Satish Varma**

Non - Executive Director

**Mr. Vinayak Hajare**

Non - Executive and  
Independent Director

# Thane One – Corporate Business IT Park



- Strategically located site off the Eastern Express Highway with easy access from all parts of Mumbai, Greater Mumbai and Thane by multiple modes of transport



- Environmentally conscious complex with a Green ambience built to **LEED PLATINUM** standards



- Car Parking with provision of charging points for electric cars & car poolers parking



- Sewage and Effluent Treatment Plant for treating and reusing water



- VAASTU Compliant



- ThaneOne awarded the "**Best Office Architecture 2013**" at Asia Pacific Property Awards, Malaysia

# Standalone Profit & Loss

Particulars (Rs. Crs)	FY19	FY18	YoY
Revenue from Operations (Net of Excise)	19.4	12.5	54.7%
Other Income	0.3	0.4	
<b>Total Revenue</b>	<b>19.7</b>	<b>12.9</b>	<b>52.7%</b>
Employee Cost	5.7	5.8	
Provision for impairment of non current investments & financials asset in associates/ Joint venture	9.0	6.0	
Other Expenses	10.9	10.1	
<b>EBITDA</b>	<b>-5.9</b>	<b>-9.0</b>	<b>34.4%</b>
<b>EBITDA Margin</b>	<b>-30.0%</b>	<b>-69.9%</b>	
Depreciation	3.8	3.8	
<b>EBIT</b>	<b>-9.7</b>	<b>-12.8</b>	<b>24.5%</b>
<b>EBIT Margin</b>	<b>-49.2%</b>	<b>-99.6%</b>	
Finance Cost	16.0	10.6	
Exceptional Item (Gain) / Loss			
<b>Profit before Tax</b>	<b>-25.6</b>	<b>-23.5</b>	<b>-9.3%</b>
<b>PBT Margin</b>	<b>-130.4%</b>	<b>-182.1%</b>	
Tax	-23.0	0.7	
<b>PAT</b>	<b>-2.67</b>	<b>-24.15</b>	<b>88.9%</b>
<b>PAT Margin %</b>	<b>-13.6%</b>	<b>-187.4%</b>	

# Standalone Balance Sheet

<b>EQUITY AND LIABILITIES (Rs in crores)</b>	<b>Mar-19</b>	<b>Mar-18</b>
<b>Equity</b>		
Equity Share capital	4.6	2.3
Other equity	55.3	62.4
<b>Sub-total - Shareholders' funds</b>	<b>59.8</b>	<b>64.7</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
Borrowings	127.1	132.0
Other financial liabilities	3.5	5.3
Provisions	1.9	0.7
Other non-current liabilities	8.7	1.7
<b>Sub-total - Non-current liabilities</b>	<b>141.2</b>	<b>139.8</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
Borrowings	6.5	5.7
Trade payables	2.7	1.8
Other financial liabilities	16.8	9.0
Other current liabilities	6.0	1.4
Provisions	0.2	0.2
<b>Sub-total - Current liabilities</b>	<b>32.2</b>	<b>18.1</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>233.2</b>	<b>222.6</b>

<b>ASSETS (Rs. In Crores)</b>	<b>Mar-19</b>	<b>Mar-18</b>
<b>Non-current assets</b>		
Property, plant and equipment	10.8	11.8
Other intangible assets	0.0	0.0
Investment Property	81.8	84.1
Investment in Associates	-	7.0
Investment in Subsidiaries	100.3	100.3
<b>Financial assets</b>		
Investments	0.6	0.1
Loans	0.0	0.3
Share Application Money	6.0	9.1
Other financial assets	1.8	2.2
Deffered Tax Asset	23.0	-
Non-current tax assets	3.3	1.0
Other non-current assets	1.7	1.6
<b>Sub-total - Non-Current Assets</b>	<b>229.2</b>	<b>217.5</b>
<b>Current assets</b>		
<b>Financial assets</b>		
Investments	1.1	1.1
Trade receivables	0.3	0.3
Cash and cash equivalents	1.1	1.3
Bank balances other than Cash and Cash equivalents	0.2	0.2
Loans	0.3	0.1
Other financial assets	0.3	0.7
Other current assets	0.8	1.4
<b>Sub-total - Current Assets</b>	<b>4.1</b>	<b>5.1</b>
Assets Classified as held for Sale		
<b>TOTAL - ASSETS</b>	<b>233.2</b>	<b>222.6</b>


The image is a composite background. On the left, there's a close-up of a laptop keyboard with keys like 'C', 'X', and 'I' visible. On the right, a silver pen lies diagonally over a financial document. The document contains a bar chart with years 2007, 2008, 2009, 2010, 2011, and 2012E on the x-axis. A green semi-transparent box is overlaid on the left side of the image, containing the text 'Performance Highlights'.

## *Performance Highlights*


# DIL Limited – Historical Performance




Revenue (Rs. Crs)




EBITDA (Rs. Crs)




PAT^ (Rs. Crs)




Cash PAT^ (Rs. Crs)



EBITDA (%)



PAT^ (%)



# Our Association with Vitamin Angels




## PROUD SUPPORTER

- A non-profit organization providing life changing vitamins to populations in need—specifically pregnant women, new mothers, and children under five.
- Vitamin Angels works to reach underserved communities in partnership with over **700 NGOs** in more than **74 countries** around the world. It reaches over **61 million** women and children for delivering vitamin solutions.
- Last year, our support allowed Vitamin Angels to reach **40,000 additional mothers and children.**

# Our Awareness Initiative: Vitamin D Guru



Fermenta Biotech Limited



An Innovative public awareness portal dedicated to spreading awareness about Vitamin D, its intake and benefits.

Aims to build a community of Vitamin D conscious health users who can share their experiences with others

Our endeavour to unlock access to millions of internet users and turn them into healthy and enriched human beings to maintain an optimum level of Vitamin D

# Our Association with NAB



Corneal Transplant (Keratoplasty)



NATIONAL ASSOCIATION FOR THE BLIND (INDIA)

••••• ••••• ••••• ••••• ••••• ••••• ••••• ••••• ••••• •••••

Promoting the interests of people with vision loss in India



Squint (Strabismus) Correction

Particular	Total Commitment
Corneal Transplant Surgeries	200
Squint Correction Surgeries	40
Educational Braille Kits	295
Grant for Diploma in Special Education (D'ED) course	1



Educational Braille Kit

## India Pharma Awards 2018 on 12<sup>th</sup> December 2018

Great Place To Work® Certified

Insights Success Magazine – April 2019

Excellence in CSR



Excellence in Export Promotion



Pharma International Excellence



## Hindustan Times Thane Ratna Award on 31<sup>st</sup> January 2019

## World HRD Congress 2018 on 16<sup>th</sup> February 2019

## Pride of Maharashtra: Best CEO of the Year 21<sup>st</sup> February 2019



National Best Employer Brand



Business Leader of the Year



Top 101 HR Minds



Manufacturing – Pharmaceuticals



# Contact Us

---

**Company :**

CIN No: L99999MH1951PLC008485

Mr. Sumesh Gandhi  
[sumesh.gandhi@dil.net](mailto:sumesh.gandhi@dil.net)

[www.dil.net](http://www.dil.net)

---

**Investor Relations Advisors :**

CIN - U74140MH2010PTC204285

Mr. Jigar Kavaia  
[jigar.kavaia@sgapl.net](mailto:jigar.kavaia@sgapl.net)  
+91 9920602034

[www.sgapl.net](http://www.sgapl.net)